Skip to content (Press Enter)
firstview insight

First View Insight

Insights with Intellect

  • HOME
  • ABOUT US
  • OUR SERVICES
    • PHARMACEUTICAL REPORTS
    • BUSINESS CONSULTING
    • COMPETITIVE INTELLIGENCE
    • PRICING & MARKET ACCESS
    • HEOR
    • FORECASTING
    • DIGITAL & SOCIAL MEDIA
  • REPORTS
  • MEDIA
    • PRESS RELEASES
    • INFOGRAPHICS
    • BLOG
    • NEWSLETTER
    • VIDEOS
  • CONTACT US
+91-7821096515 sales@firstviewinsight.com
+91-7821096515 sales@firstviewinsight.com
firstview insight

First View Insight

Insights with Intellect

  • HOME
  • ABOUT US
  • OUR SERVICES
    • PHARMACEUTICAL REPORTS
    • BUSINESS CONSULTING
    • COMPETITIVE INTELLIGENCE
    • PRICING & MARKET ACCESS
    • HEOR
    • FORECASTING
    • DIGITAL & SOCIAL MEDIA
  • REPORTS
  • MEDIA
    • PRESS RELEASES
    • INFOGRAPHICS
    • BLOG
    • NEWSLETTER
    • VIDEOS
  • CONTACT US

HEALTHCARE SYSTEM IN CANADA

Posted by FirstView InsightBlogCADTH, CANADA, healthcaresystem, PMPRBPosted on December 23, 2019

HIGHLIGHTS OF THE CANADIAN HEALTHCARE SYSTEM Access to healthcare is based on the need rather than the affordability is the …

Continue Reading

Humira patent litigation was resolved between AbbVie and Boehringer Ingelheim

Posted by FirstView InsightUncategorizedPosted on October 2, 2019

Humira has announced that the patent litigation was resolved between AbbVie and Boehringer Ingelheim. Based on the resolution, AbbVie will …

Continue Reading

EMA’s CHMP given a positive opinion on Lorviqua for the treatment of previously treated ALK-positive

Posted by FirstView InsightUncategorizedPosted on October 2, 2019

European Commission has granted conditional approval for Loqviqua for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung …

Continue Reading

SOBI acquired by Dova Pharmaceuticals

Posted by FirstView InsightPress ReleasesDova Pharmaceuticals, EMA, SOBI, US FDAPosted on September 30, 2019

Swedish Orphan Biovitrum AB (SOBI) has announced that it made an agreement to acquire Dova Pharmaceuticals. As per the agreement, …

Continue Reading

Cosentyx trial data indicate that the drug is ready to get approval for the fourth indication

Posted by FirstView InsightPress ReleasesCosentyx, non-radiographic axial spondyloarthritis, nr-axSpA, US FDAPosted on September 23, 2019

Novartis announced the trial data of Cosentyx indicated for axial spondyloarthritis. The results of a 16-week PREVENT study were announced; …

Continue Reading

CHMP Positive Opinions: September

Posted by FirstView InsightPress ReleasesCHMP, Positive Opinions, SeptemberPosted on September 23, 2019

CHMP positive opinion of September New approvals · Qtrilmet of AstraZeneca · Rhokiinsa of Aerie Pharmaceuticals · Xospata of Astellas …

Continue Reading

Safinamide was approved in Japan

Posted by FirstView InsightPress ReleasesEisai, Japan, Parkinson’s, SafinamidePosted on September 23, 2019

Eisai and Meiji Seika Pharma announced that Equfina tablets were approved in Japan for the treatment of Parkinson’s disease. Meiji …

Continue Reading

Novartis capmatinib (INC280) received breakthrough designation by FDA

Posted by FirstView InsightPress Releasesbreakthrough designation, capmatinib, Novartis, US FDAPosted on September 18, 2019

Novartis announced that capmatinib (INC280) received the breakthrough designation. The product is the first drug indicated for the first line …

Continue Reading

Lundbeck acquired Alder BioPharmaceuticals – a company specialized in migraine treatment

Posted by FirstView InsightPress Releasesacquisitions, Alder BioPharmaceuticals, LundbeckPosted on September 18, 2019

Lundbeck announced that it acquired Alder BioPharmaceuticals, a company specialized in the development of therapies indicated for the treatment of …

Continue Reading

AstraZeneca’s Farxiga received fast track designation from US FDA

Posted by FirstView InsightPress ReleasesAstraZeneca, fast track designation, US FDAPosted on September 17, 2019

AstraZeneca announced that Farxiga (dapagliflozin) received fast track designation from the US Food and Drug Administration (FDA). The indication for …

Continue Reading

Posts navigation

Page 1 Page 2 … Page 6

Recent Posts

  • HEALTHCARE SYSTEM IN CANADA
  • Humira patent litigation was resolved between AbbVie and Boehringer Ingelheim
  • EMA’s CHMP given a positive opinion on Lorviqua for the treatment of previously treated ALK-positive
  • SOBI acquired by Dova Pharmaceuticals
  • Cosentyx trial data indicate that the drug is ready to get approval for the fourth indication
Copyright @ 2020 First View Insight. All Rights Reserved.
Construction Company | Developed By Rara Theme Powered by WordPress.